Winston Pharmaceuticals, Inc. Announces Election of New Chief Executive Officer and Chairman of the Board of Directors
29 7월 2009 - 6:00AM
Business Wire
Winston Pharmaceuticals, Inc. (OTC BB: WPHM) (the “Company”)
today announced that Joel E. Bernstein, M.D., the founder of
Winston Laboratories, Inc., the Company’s wholly-owned subsidiary
(“Winston Labs”), will resign as Chairman of the Board of
Directors, President and Chief Executive Officer of the Company,
effective September 22, 2009, and that the Company’s Board of
Directors has elected Jeffrey R. Bernstein, Ph.D. to assume the
position of President and Chief Executive Officer, effective as of
such date. The Board of Directors also appointed Robert A. Yolles,
J.D., a member of the Company’s Board of Directors since 2008, to
assume the position of Chairman of the Board, effective September
22, 2009. Dr. Joel Bernstein will remain as a director of the
Company and serve as a consultant, primarily in the areas of
product and business development.
Dr. Jeffrey Bernstein graduated Amherst College summa cum laude,
was a Fulbright Scholar resident in Japan, and received an A.M. and
Ph.D. in Business Economics from Harvard University. Following
stints as an Advanced Research Fellow at Harvard and an academic
position in public affairs and applied economics at the University
of Wisconsin – Madison, Dr. Jeffrey Bernstein joined Winston Labs
in 2001 where he moved through a succession of positions
culminating in Chief Operating Officer from 2005 – 2007. On
September 30, 2007, Dr. Jeffrey Bernstein resigned from
Winston Labs, and entered into a consulting agreement with such
company, effective as of October 1, 2007. He has served as a
consultant to Winston Labs since 2007, and to the Company since the
consummation of its merger transaction with Winston Labs on
September 25, 2008.
Mr. Yolles received his B.A. and J.D. from Northwestern
University and is the retired co-chairman of the worldwide
corporate practice and, subsequently, the finance practice of the
law firm Jones Day.
“I am very pleased that Jeffrey has agreed to succeed me as CEO
of Winston,” said Joel Bernstein. “Jeffrey’s knowledge of the
business aspects of the pharmaceutical industry is nonpareil, and
with the addition of his youth and vigor, he provides us with a top
officer with the requisite skill set to take the Company into its
next phase of its growth. I will remain actively involved with the
Company’s R&D and business development programs.”
Bob Yolles stated, “I have worked closely and successfully with
Jeffrey in the past during my tenure as Chairman of the Board of
Winston Labs, and I welcome the opportunity for us to join together
as the Company moves forward.”
About Winston Pharmaceuticals
Winston Pharmaceuticals, Inc. is a development stage
pharmaceutical company focused on pain control. The Company is
developing products for large pain control markets, as well as for
niche markets, where there are still significant unmet needs for
pain management options with improved efficacy, safety, and
tolerability profiles. The Company’s product candidates span a
range of pain indications, including arthritis, neuropathic pain,
cancer pain, post-operative pain, cluster headache and chronic
daily headache.
This press release contains “forward-looking statements,” as
that term is defined under the Private Securities Litigation Reform
Act of 1995 (PSLRA), regarding product development efforts and
other non-historical facts about expectations, beliefs or
intentions regarding the business, technologies and products,
financial condition, strategies or prospects. Many factors could
cause actual activities or results to differ materially from the
activities and results anticipated in forward-looking statements.
These factors include those described in our filings with the
Securities and Exchange Commission, as well as risks inherent in
funding, developing and obtaining regulatory approvals of new,
commercially-viable and competitive products and treatments,
including the risks that any products under development may fail,
may not achieve the expected results or effectiveness and may not
generate data that would support the approval or marketing of
products for the ailments being studied or for other ailments. In
addition, forward-looking statements also may be adversely affected
by general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products and indications, manufacturing
issues that may arise, patent positions and litigation, among other
factors. We do not undertake any obligation to update
forward-looking statements. We intend that all forward-looking
statements be subject to the safe-harbor provisions of the
PSLRA.
Winston Pharmaceuticals (CE) (USOTC:WPHM)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Winston Pharmaceuticals (CE) (USOTC:WPHM)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
